SELLAS Life Sciences Group Management
Management criteria checks 2/4
SELLAS Life Sciences Group's CEO is Angelos Stergiou, appointed in Dec 2012, has a tenure of 11.42 years. total yearly compensation is $1.95M, comprised of 30.4% salary and 69.6% bonuses, including company stock and options. directly owns 0.67% of the company’s shares, worth $479.10K. The average tenure of the management team and the board of directors is 4.3 years and 6.4 years respectively.
Key information
Angelos Stergiou
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 30.4% |
| CEO tenure | 11.4yrs |
| CEO ownership | 0.7% |
| Management average tenure | 4.3yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely
Jul 13
SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely
Sep 20SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study
Aug 09We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully
Mar 08Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?
Nov 23Companies Like SELLAS Life Sciences Group (NASDAQ:SLS) Are In A Position To Invest In Growth
Jul 19SELLAS Life Sciences updates on at-the-market offering
Jun 02SELLAS Life Sciences jumps 43% after Reddit mentions
Feb 03Sellas' galinpepimut-S combo shows promising action in early-stage solid tumor studies
Dec 21Sellas Life Sciences strengthens balance sheet with addition of $30.5M
Dec 17Sellas Life Sciences prices $16.2M direct offering
Dec 14Nelipepimut-S data from breast cancer study fails to lift SELLAS Life Sciences
Dec 11SELLAS and 3D Medicines in exclusive license agreement for development and commercialization of GPS and GPS+ in Greater China
Dec 07SELLAS Life Sciences EPS misses by $0.26
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$37m |
| Sep 30 2023 | n/a | n/a | -US$38m |
| Jun 30 2023 | n/a | n/a | -US$36m |
| Mar 31 2023 | n/a | n/a | -US$36m |
| Dec 31 2022 | US$2m | US$594k | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$39m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$2m | US$565k | -US$21m |
| Sep 30 2021 | n/a | n/a | -US$18m |
| Jun 30 2021 | n/a | n/a | -US$15m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$1m | US$541k | -US$17m |
| Sep 30 2020 | n/a | n/a | -US$21m |
| Jun 30 2020 | n/a | n/a | -US$28m |
| Mar 31 2020 | n/a | n/a | -US$27m |
| Dec 31 2019 | US$1m | US$630k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$34m |
| Jun 30 2019 | n/a | n/a | -US$32m |
| Mar 31 2019 | n/a | n/a | -US$36m |
| Dec 31 2018 | US$1m | US$549k | -US$41m |
| Sep 30 2018 | n/a | n/a | -US$37m |
| Jun 30 2018 | n/a | n/a | -US$32m |
| Mar 31 2018 | n/a | n/a | -US$30m |
| Dec 31 2017 | US$729k | US$400k | -US$24m |
Compensation vs Market: Angelos's total compensation ($USD1.95M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Angelos's compensation has increased whilst the company is unprofitable.
CEO
Angelos Stergiou (47 yo)
11.4yrs
Tenure
US$1,952,245
Compensation
Dr. Angelos M. Stergiou, MD, Sc.D. h.c., is the Founder, President, Chief Executive Officer and Director of SELLAS Life Sciences Group, Inc. (formerly known as SELLAS Life Sciences Group AG) (formerly, Sel...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 11.4yrs | US$1.95m | 0.67% $ 479.1k | |
| Senior VP & CFO | 6.4yrs | US$436.73k | 0.18% $ 129.7k | |
| VP, Associate General Counsel & Head of Compliance | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | 4.3yrs | US$859.54k | no data | |
| VP and Head of Regulatory Affairs | 1.3yrs | no data | no data |
4.3yrs
Average Tenure
47yo
Average Age
Experienced Management: SLS's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 11.4yrs | US$1.95m | 0.67% $ 479.1k | |
| Independent Director | 6.4yrs | US$117.85k | 0.0078% $ 5.6k | |
| Independent Director | 6.4yrs | US$117.85k | 0.0078% $ 5.6k | |
| Independent Director | 6.4yrs | US$109.85k | 0.0081% $ 5.8k | |
| Independent Chairman | 6.4yrs | US$147.85k | 0.0078% $ 5.6k | |
| Chairman of Scientific Advisory Board | 7.5yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 8.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.5yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.8yrs | US$70.32k | 0.0044% $ 3.2k |
6.4yrs
Average Tenure
64.5yo
Average Age
Experienced Board: SLS's board of directors are considered experienced (6.4 years average tenure).